New epilepsy drug shows promise for long-term seizure control

NCT ID NCT07563634

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of brivaracetam, a drug added to existing epilepsy treatments for people with uncontrolled focal seizures. 141 Chinese adults who completed a prior trial took brivaracetam for up to a year or more. Researchers tracked side effects and seizure frequency to see if the drug remains safe and effective over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

brivaracetam

What this could lead to

If successful, this could confirm brivaracetam as a safe and effective long-term add-on treatment for people with focal epilepsy that isn't controlled by other medications.

What could go wrong

This is an open-label study with no placebo group, so results may be less reliable. Side effects like dizziness or drowsiness are possible, and not everyone may benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY, FOCAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200040, China